Medical Applications of PEG: Long-Acting Modification, Precision Linkers, and Nanodelivery

Polyethylene glycol (PEG) is a hydrophilic polymer widely used in medicine. Its high water solubility, flexible chain structure, and diverse options for end-group modification make PEG and its derivatives useful as pharmaceutical excipients, for modifying drug molecules, and for constructing delivery carriers. Applications span small-molecule drugs, protein and peptide therapeutics, antibody–drug conjugates, and nucleic acid therapeutics. Selecting appropriate chain lengths, end groups, and linkages can modulate drug solubility, stability, behavior in vivo, and release.

PEG-related medicines have achieved substantial commercial scale. According to companies’ reported 2025 results, the PEGylated antibody fragment Cimzia generated net sales of EUR 1.954 billion; Trodelvy, an antibody–drug conjugate containing a PEG linker, generated sales of USD 1.397 billion; and Zilbrysq, a peptide drug containing a precision PEG24 linker, generated net sales of EUR 217 million, approximately three times its 2024 sales. These products demonstrate commercial applications of PEG in protein modification, peptide drug design, and ADC development. Its value extends beyond conventional modification for prolonged action to functional linkers of defined length.

China has also continued to make progress in PEG-related medicines and delivery formulations. Domestically developed products including peginterferon alfa-2b, PEGylated growth hormone, and polyethylene glycol loxenatide have been approved, demonstrating applications of PEG modification in long-acting protein and peptide drugs. In nucleic acid delivery, Yuxi Walvax’s COVID-19 mRNA vaccine received registration approval from China’s National Medical Products Administration (NMPA) in September 2026. These developments show that domestic PEG applications now encompass long-acting biologics and mRNA delivery formulations and are supporting the development and use of related functional materials and pharmaceutical excipients.

PEG takes different forms and serves different roles across applications. It may be used directly as a formulation excipient, covalently attached to an active molecule, or incorporated into delivery systems such as liposomes, lipid nanoparticles (LNPs), and hydrogels. Short PEG or oligoethylene glycol (OEG) of defined length can also serve as a linker or hydrophilic spacer between functional modules.

Current pharmaceutical applications of PEG fall into the following main categories:

(1) Protein and peptide modification. PEG is covalently attached to proteins, peptides, or their prodrugs to modulate drug stability, exposure in vivo, and release.
(2) Precision linkers. Defined-length PEG or OEG connects peptides, lipids, and other functional groups to control spacing, hydrophilicity, and structural consistency.
(3) ADC linkers. PEG or OEG segments are incorporated into the linkage between an antibody and its payload to improve linker hydrophilicity and modulate the conjugate’s overall properties.
(4) Liposomes and lipid nanoparticles (LNPs). PEG lipids contribute to particle surfaces, assist formulation assembly, and modulate colloidal stability and behavior in vivo.
(5) Other sustained-release carriers. PEG is incorporated into hydrogels or copolymers to form local drug depots and regulate release.

The following tables summarize applications of PEG and OEG in approved medicines and delivery formulations in China and internationally. They present representative products, their PEG or OEG structures, and their main functions, together with updates on selected investigational programs.

Table 1 Representative Applications of PEG and OEG in Medicines and Delivery Formulations

Application Category	Brand and Generic Name	Company	PEG Structure or Linkage	Main Application	Year of First FDA Approval
Protein and peptide modification	Yuviwel — navepegritide	Ascendis	Two sets of branched 20 kDa mPEG; releasable CNP prodrug	Achondroplasia	2026; accelerated approval
	Loargys — pegzilarginase-nbln	Immedica	Arginase modified at multiple sites with 5 kDa mPEG	Arginase 1 deficiency	2026
	Yipeisheng — PEGylated growth hormone	Xiamen Amoytop Biotech	Growth hormone modified with one 40 kDa Y-shaped branched PEG	Growth failure due to growth hormone deficiency in children aged 3 years and older	2025; China NMPA
	Yorvipath — palopegteriparatide	Ascendis	Approximately 40 kDa PEG carrier; releasable PTH prodrug	Hypoparathyroidism	2024
	Zilbrysq — zilucoplan	UCB	Defined-length PEG24 connecting the cyclic peptide to its lipid side chain	Generalized myasthenia gravis	2023
	Elfabrio — pegunigalsidase alfa-iwxj	Chiesi / Protalix	An average of approximately nine 2.3 kDa PEG chains crosslink the enzyme dimer	Fabry disease	2023
	Syfovre — pegcetacoplan	Apellis	Approximately 40 kDa linear PEG connects two cyclic peptides	Geographic atrophy secondary to age-related macular degeneration	2023
	Rolvedon — eflapegrastim-xnst	Spectrum / Hanmi	3.4 kDa PEG links a G-CSF analogue to Fc	Reduction in the risk of chemotherapy-related febrile neutropenia	2022
	Besremi — ropeginterferon alfa-2b-njft	PharmaEssentia	Interferon modified with approximately 40 kDa branched PEG	Polycythemia vera	2021
	Skytrofa — lonapegsomatropin-tcgd	Ascendis	Approximately 40 kDa branched PEG; releasable growth hormone prodrug	Growth hormone deficiency	2021
	Empaveli — pegcetacoplan	Apellis	Approximately 40 kDa linear PEG connects two cyclic peptides	Paroxysmal nocturnal hemoglobinuria and other indications	2021
	Esperoct — turoctocog alfa pegol	Novo Nordisk	Site-specific glycoPEGylation of factor VIII with 40 kDa PEG	Hemophilia A	2019
	Fulaimei — polyethylene glycol loxenatide	Jiangsu Hansoh Pharmaceutical	Approximately 40 kDa branched PEG covalently linked to the thiol of loxenatide through a maleimide group	Glycemic control in adults with type 2 diabetes	2019; China NMPA
	Palynziq — pegvaliase-pqpz	BioMarin	Phenylalanine ammonia lyase modified at multiple sites with individual 20 kDa PEG chains	Phenylketonuria	2018
	Revcovi — elapegademase-lvlr	Leadiant	Recombinant adenosine deaminase covalently modified with mPEG	Severe combined immunodeficiency associated with ADA deficiency	2018
	Asparlas — calaspargase pegol-mknl	Servier	Asparaginase modified with approximately 31–39 chains of 5 kDa SC-PEG	Acute lymphoblastic leukemia	2018
	Jivi — damoctocog alfa pegol	Bayer	Factor VIII modified with 60 kDa branched PEG	Hemophilia A	2018
	Rebinyn — nonacog beta pegol	Novo Nordisk	Site-specific glycoPEGylation of factor IX with 40 kDa PEG	Hemophilia B	2017
	Pegberon — peginterferon alfa-2b	Xiamen Amoytop Biotech	Recombinant human interferon alfa-2b covalently modified with 40 kDa Y-shaped branched PEG	Chronic hepatitis B and chronic hepatitis C in adults	2016; China, former CFDA
	Adynovate — rurioctocog alfa pegol	Baxalta / Takeda	Factor VIII modified with individual 20 kDa PEG chains	Hemophilia A	2015
	Plegridy — peginterferon beta-1a	Biogen	Interferon modified with 20 kDa linear mPEG	Relapsing multiple sclerosis	2014
	Omontys — peginesatide	Affymax / Takeda	Erythropoietin-mimetic peptide modified with approximately 40 kDa branched PEG	Anemia associated with chronic kidney disease	2012; approval withdrawn
	Sylatron — peginterferon alfa-2b	Merck	Interferon modified with 12 kDa mPEG	Adjuvant treatment of melanoma	2011; discontinued
	Krystexxa — pegloticase	Savient	Uricase modified at multiple sites with individual 10 kDa mPEG chains	Chronic gout refractory to conventional treatment	2010
	Cimzia — certolizumab pegol	UCB	Anti-TNFα Fab′ modified with approximately 40 kDa branched PEG	Inflammatory diseases including rheumatoid arthritis	2008
	Mircera — methoxy PEG-epoetin beta	Roche	Erythropoietin modified with approximately 30 kDa linear mPEG	Anemia associated with chronic kidney disease	2007
	Somavert — pegvisomant	Pfizer	Growth hormone receptor antagonist modified with individual 5 kDa PEG chains	Acromegaly	2003
	Neulasta — pegfilgrastim	Amgen	G-CSF modified with 20 kDa linear mPEG	Reduction in the risk of chemotherapy-related febrile neutropenia and other indications	2002
	Pegasys — peginterferon alfa-2a	Roche	Interferon modified with approximately 40 kDa branched PEG	Chronic hepatitis B and C	2002
	Pegintron — peginterferon alfa-2b	Schering / Merck	Interferon modified with 12 kDa mPEG	Chronic hepatitis C	2001; discontinued
	Oncaspar — pegaspargase	Enzon	Asparaginase modified at multiple sites with individual 5 kDa mPEG chains	Acute lymphoblastic leukemia	1994
	Adagen — pegademase bovine	Enzon	Bovine adenosine deaminase modified with approximately 11–17 chains of 5 kDa mPEG	Severe combined immunodeficiency associated with ADA deficiency	1990; discontinued
PEGylated growth factors	Ennumo — pegfilgrastim-pccg	Accord BioPharma	Approximately 20 kDa PEG covalently attached to G-CSF	Prevention of post-chemotherapy neutropenia and related infection risk	2026
	Armlupeg — pegfilgrastim-unne	Lupin	Approximately 20 kDa PEG covalently attached to G-CSF		2025
	Stimufend — pegfilgrastim-fpgk	Fresenius Kabi	Approximately 20 kDa PEG covalently attached to G-CSF		2022
	Fylnetra — pegfilgrastim-pbbk	Amneal	Approximately 20 kDa PEG covalently attached to G-CSF		2022
	Nyvepria — pegfilgrastim-apgf	Pfizer	Approximately 20 kDa PEG covalently attached to G-CSF		2020
	Ziextenzo — pegfilgrastim-bmez	Sandoz	Approximately 20 kDa PEG covalently attached to G-CSF		2019
	Udenyca — pegfilgrastim-cbqv	Coherus	Approximately 20 kDa PEG covalently attached to G-CSF		2018
	Fulphila — pegfilgrastim-jmdb	Mylan / Biocon	Approximately 20 kDa PEG covalently attached to G-CSF		2018
Nucleic acid aptamers	Izervay — avacincaptad pegol	Iveric Bio / Astellas	Approximately 43 kDa branched PEG attached to an RNA aptamer	Geographic atrophy	2023
Nucleic acid aptamers	Macugen — pegaptanib sodium	Eyetech / Pfizer	Approximately 40 kDa PEG attached to an RNA aptamer	Wet age-related macular degeneration	2004; discontinued
Small molecules and short OEG	Movantik — naloxegol	AstraZeneca / Nektar	Defined-length PEG7 side chain	Opioid-induced constipation	2014
	Asclera — polidocanol	Kreussler	C12 alkyl group with a polyoxyethylene chain averaging approximately 9 repeat units; average molecular weight of the whole molecule approximately 600 Da	Sclerotherapy of spider and reticular veins of the lower limbs	2010
	Varithena — polidocanol injectable foam	Biocompatibles	Same polyoxyethylene structure as polidocanol; foam formulation	Certain varicose veins of the lower limbs	2013
Lipidated peptide drugs with short OEG spacers	Ozempic / Rybelsus / Wegovy — semaglutide	Novo Nordisk	Two AEEA-type OEG spacer units between the peptide and a C18 fatty diacid	Type 2 diabetes or weight management, depending on the brand	2017 / 2019 / 2021
	Mounjaro / Zepbound — tirzepatide	Eli Lilly	Two AEEA-type OEG spacer units connected to a C20 fatty diacid side chain	Type 2 diabetes or weight management, depending on the brand	2022 / 2023
	Awiqli — insulin icodec-abae	Novo Nordisk	Lipid side chain containing two AEEA-type OEG spacer units	Type 2 diabetes in adults	2026
ADCs with PEG linkers	Trodelvy — sacituzumab govitecan-hziy	Immunomedics / Gilead	CL2A linker containing PEG8; SN-38 payload	Certain breast cancers	2020
ADCs with PEG linkers	Zynlonta — loncastuximab tesirine-lpyl	ADC Therapeutics	Tesirine linker containing PEG8; PBD dimer payload	Relapsed or refractory large B-cell lymphoma	2021
Sustained-release delivery carriers	Dextenza — dexamethasone insert	Ocular Therapeutix	PEG-based hydrogel containing dexamethasone	Postoperative ocular inflammation and pain and other indications	2018
	Uzedy — risperidone	Teva / MedinCell	Copolymer containing PEG and polylactide segments for a long-acting injectable formulation	Schizophrenia and other indications	2023
	Sustol — granisetron	Heron	Poly(ortho ester) carrier containing triethylene glycol, together with mPEG550	Prevention of chemotherapy-related nausea and vomiting	2016; discontinued
PEG-modified nanoparticles and LNPs	Doxil — liposomal doxorubicin	Sequus	MPEG2000-DSPE; PEGylated liposome	Ovarian cancer, Kaposi’s sarcoma, multiple myeloma, and other indications	1995
	Onivyde — liposomal irinotecan	Merrimack	MPEG2000-DSPE; PEGylated liposome	Pancreatic adenocarcinoma	2015
	Onpattro — patisiran	Alnylam	PEG2000-C-DMG; siRNA-LNP	Polyneuropathy associated with hereditary transthyretin amyloidosis	2018
	Comirnaty — COVID-19 mRNA vaccine	BioNTech / Pfizer	ALC-0159, a lipid containing approximately 2 kDa PEG	Prevention of COVID-19	2021
	Spikevax — COVID-19 mRNA vaccine	Moderna	PEG2000-DMG; mRNA-LNP	Prevention of COVID-19	2022
	mResvia — RSV vaccine	Moderna	PEG2000-DMG; mRNA-LNP	Prevention of RSV-associated lower respiratory tract disease	2024
	mNexspike — COVID-19 mRNA vaccine	Moderna	PEG2000-DMG; mRNA-LNP	Prevention of COVID-19	2025
	mFlusiva — influenza mRNA vaccine	Moderna	PEG2000-DMG; mRNA-LNP	Prevention of influenza in people aged 50 years and older	2026
	COVID-19 Vaccine mRNA	Yuxi Walvax, a subsidiary of Walvax Biotechnology	DMG-PEG2000; mRNA-LNP; average PEG segment molecular weight approximately 2 kDa	Prevention of COVID-19 in people aged 18 years and older	2026; China NMPA
	Intismeran autogene (V940 / mRNA-4157)	Merck / Moderna	PEG-DMG; mRNA-LNP	Personalized cancer immunotherapy under investigation as adjuvant treatment after melanoma surgery	Not yet approved; Phase 3 success

Note: Unless otherwise specified, approval years refer to the first full approval by the US FDA. Entries marked "China" give the year of first approval in China. V940 is an investigational program.

In addition to drug modification and delivery carrier construction, PEG can be used as a pharmaceutical excipient, an active ingredient with a direct therapeutic effect, and a medical material. Representative applications are listed below.

Table 2 Representative Uses of PEG as a Formulation Excipient Active Ingredient and Medical Material

Application Category	Product	PEG Type	Main Role or Use	FDA Approval Date
Formulation excipients	Gris-PEG — griseofulvin	PEG 400 and PEG 8000	Oral formulation of ultramicrosize griseofulvin; PEG serves as a formulation excipient	1975
	Targretin — bexarotene capsules	PEG 400	Component of the soft capsule fill in oral bexarotene formulations	1999
	Busulfex — busulfan injection	PEG 400	Forms the solvent system for busulfan injection together with other solvents	1999
	Walvax COVID-19 mRNA vaccine	DMG-PEG2000	Used in the LNP delivery system of Yuxi Walvax’s COVID-19 mRNA vaccine	2026; China CDE associated review, status A
Active ingredients	MiraLax	PEG 3350	Osmotic laxative; PEG itself is the active ingredient	1999
Active ingredients	GoLYTELY	PEG 3350 and electrolytes	Bowel cleansing before colon examination; distinct from use as an ordinary formulation excipient	1984
Excipients for contrast agents	Lumason — sulfur hexafluoride microspheres	PEG 4000	Sulfur hexafluoride microbubble ultrasound contrast agent; PEG is a free excipient in the formulation	2014
Excipients for contrast agents	Definity — perflutren lipid microspheres	MPEG5000-DPPE	Perflutren microbubble ultrasound contrast agent; the PEG lipid forms part of the microbubble shell	2001
Hydrogel sealants	CoSeal Surgical Sealant	Two reactive PEG derivatives that crosslink upon mixing to form a hydrogel	Adjunctive hemostasis and mechanical sealing in vascular reconstruction	2001
Hydrogel sealants	DuraSeal Dural Sealant System	PEG ester crosslinked with trilysine to form a hydrogel	Adjunctive watertight dural closure after suturing in cranial surgery	2005

Precision Polymer Products and Custom Synthesis

From defined-length molecular linkers to the surface materials of complex formulations, drug development is moving beyond selecting a nominal PEG molecular weight toward the joint design of chain length, end groups, topology, and linkages. Precision Polymer offers a range of PEG products and custom synthesis services to support research on drug modification, ADC linkers, nucleic acid delivery, and sustained-release systems.

The following are Precision Polymer’s product categories and selected representative products:

Monofunctional Precision PEG

Methoxy-PEG-Hydroxyl

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Methoxy-PEG-Amine

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Methoxy-PEG-Carboxyl

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Methoxy-PEG-NHS Ester

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Methoxy-PEG-Maleimide

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Cyclic PEG with a PEG Arm and Terminal Hydroxyl

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96

Bifunctional Precision PEG

Hydroxyl-PEG-Hydroxyl

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Amine-PEG-Amine

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Thiol-PEG-Thiol

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Amine-PEG-Carboxyl

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Maleimide-PEG-NHS Ester

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Fmoc-Protected Amine-PEG-Carboxyl

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Tosylate-PEG-Tosylate

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Multifunctional Precision PEG

Y-Shaped Two-Arm Methoxy-PEG-NHS Ester

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Y-Shaped Two-Arm Methoxy-PEG-Maleimide

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Four-Arm PEG-Hydroxyl

Available n values: n=4 · n=8 · n=12 · n=24 · n=45 · n=96

Four-Arm PEG-NHS Ester

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Four-Arm PEG-Thiol

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Eight-Arm PEG-Maleimide

Available n values: n=4 · n=8 · n=12 · n=24 · n=45 · n=96

Precision PEG ADC Linkers

Maleimide-PEG-Val-Cit-PAB-OH

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Maleimide-PEG-Val-Ala-PAB-PNP

Available n values: n=4 · n=8 · n=12 · n=16 · n=24 · n=32

Maleimide-PEG-Gly-Gly-Phe-Gly-Carboxyl

Available n values: n=4 · n=8 · n=12 · n=16 · n=24 · n=32

Maleimide-PEG-Disulfide-Carboxyl

Available n values: n=4 · n=8 · n=12 · n=16 · n=24 · n=32

Amine-PEG-Val-Cit-PAB-OH

Available n values: n=4 · n=8 · n=12 · n=16 · n=24 · n=32

DBCO-PEG-Val-Cit-PAB-OH

Available n values: n=4 · n=8 · n=12 · n=16 · n=24 · n=32

Precision PEG Lipids and Excipients

Methoxy-PEG-DSPE

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Methoxy-PEG-DMG

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Methoxy-PEG-DMA

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Methoxy-PEG-DPPE

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Methoxy-PEG-Cholesterol

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Maleimide-PEG-DSPE

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Cyclic PEG with a PEG Arm and Terminal DSPE

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Polysorbate 80

View product

Precision PEG Block Copolymers

Methoxy-PEG-block-poly(D,L-lactide)

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Methoxy-PEG-block-polycaprolactone

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Methoxy-PEG-block-poly(lactic-co-glycolic acid)

Available n values: n=4 · n=8 · n=12 · n=24 · n=45 · n=96

Methoxy-PEG-block-poly(trimethylene carbonate)

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Methoxy-PEG-block-polysarcosine

Available n values: n=4 · n=8 · n=12 · n=24 · n=45 · n=96

Other Precision Polymers

Precision Polyglycerol

Available n values: n=8 · n=16 · n=24 · n=32

Precision Poly(D,L-lactide)

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Precision Polysarcosine

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

DSPE-poly(oligo(ethylene glycol) methyl ether methacrylate)

Available n values: n=8 · n=16 · n=21 · n=32 · n=45 · n=64

Fluorescent Dyes

Fluorescein-PEG-NHS Ester

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Cy3-PEG-NHS Ester

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Cy5-PEG-Maleimide

Available n values: n=4 · n=8 · n=12 · n=24 · n=45 · n=96

Cy7-PEG-NHS Ester

Available n values: n=8 · n=16 · n=24 · n=32 · n=45 · n=64

Click Chemistry Reagents

Amine-PEG-Azide

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

Alkyne-PEG-Hydroxyl

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

DBCO-PEG-NHS Ester

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192

TCO-PEG-NHS Ester

Available n values: n=4 · n=6 · n=8 · n=12 · n=16 · n=24 · n=32 · n=45 · n=64 · n=96 · n=112 · n=192